Research Network Research Articles

Effectiveness of emotion-focused therapy: Main results of a practice–research network study

Background Emotion-Focused Therapy is one of the evidence-based psychotherapies for a range of psychological problems. While most evidence was gained from randomized controlled studies or process research at university settings, there is a need for more outcome research conducted within practitioner–researcher networks assessing the effectiveness of Emotion-Focused Therapy in private practice. Methods A total of N = 70 clients with a variety of psychiatric disorders have been included in the bi-national practitioner researcher network for Emotion-focused Therapy Switzerland–Germany. Symptom change was assessed using CORE-OM, BDI-II, IIP and WSAS. Therapist adherence was assessed by the self-reported version of the PCEPS. Pre–post-follow-up analyses were conducted using paired sample t-tests and hierarchical linear modeling. Results Pre–post-assessment shows small to medium effect sizes for all outcome measures (except for interpersonal problems which did not change). Symptom reduction is maintained for CORE, BDI and WSAS, and increased for IIP at 3 and 6 months follow-up. Therapist adherence is good to excellent in this sample. Conclusions Emotion-Focused Therapy is effective in the real-world practice, as suggested by the small to moderate effect sizes. The smaller effects found in the current study as compared to randomized controlled trials are consistent with the literature and suggest that EFT remains moderately effective when applied in a naturalistic context.

Mindfulness and consumer behavior: a bibliometric analysis of themes and trends over 20 years

Mindlessness, or lack of awareness, is deeply rooted in society and reinforced by the constant stimuli from marketing practices, leading to unhealthy and unsustainable consequences for individuals, society, and the environment. In consumer behavior, this manifests as impulsive or excessive purchasing, which undermines well-being and happiness rather than enhancing them. Mindfulness has emerged as a potential solution to mindless consumption that, fostering change from the inside out, not only benefits personal well-being but also contributes to the broader well-being of society. Consumer behavior and mindfulness have been studied independently in fields such as psychology and sociology for several decades. However, the joint study and application of these areas have gained prominence in recent years, driven by the expanding practice and growing academic interest in mindfulness. This paper aims to contribute to this research field by conducting a comprehensive analysis of the key elements that shape and drive research in mindfulness and consumer behavior over the past two decades. Using a bibliometric analysis of 198 articles from the Web of Science and Scopus databases, the study identifies leading authors, institutions, countries, journals, and collaborative research networks, along with core thematic areas within the field. This research can serve as a foundation for future research and guide organizations and institutions in understanding potential shifts in consumer behavior associated with mindfulness practices. By positioning mindfulness as an integral part of the transformation in consumption behaviors, organizations may support and adapt to a more harmonious and sustainable future centered on universal well-being and the prioritization of beneficial consumption practices.

Minimum elements for reporting a feasibility assessment of algorithms based on routinely collected health data for multi-jurisdiction use: Health Data Research Network Canada recommendations

Minimum elements for reporting a feasibility assessment of algorithms based on routinely collected health data for multi-jurisdiction use: Health Data Research Network Canada recommendations

Communication-efficient federated learning of temporal effects on opioid use disorder with data from distributed research networks.

To develop a distributed algorithm to fit multi-center Cox regression models with time-varying coefficients to facilitate privacy-preserving data integration across multiple health systems. The Cox model with time-varying coefficients relaxes the proportional hazards assumption of the usual Cox model and is particularly useful to model time-to-event outcomes. We proposed a One-shot Distributed Algorithm to fit multi-center Cox regression models with Time varying coefficients (ODACT). This algorithm constructed a surrogate likelihood function to approximate the Cox partial likelihood function, using patient-level data from a lead site and aggregated data from other sites. The performance of ODACT was demonstrated by simulation and a real-world study of opioid use disorder (OUD) using decentralized data from a large clinical research network across 5 sites with 69163 subjects. The ODACT method precisely estimated the time-varying effects over time. In the simulation study, ODACT always achieved estimation close to that of the pooled analysis, while the meta-estimator showed considerable amount of bias. In the OUD study, the bias of the estimated hazard ratios by ODACT are smaller than those of the meta-estimator for all 7 risk factors at almost all of the time points from 0 to 2.5 years. The greatest bias of the meta-estimator was for the effects of age ≥65 years, and smoking. ODACT is a privacy-preserving and communication-efficient method for analyzing multi-center time-to-event data which allows the covariates' effects to be time-varying. ODACT provides estimates close to the pooled estimator and substantially outperforms the meta-analysis estimator. The proposed ODACT is a privacy-preserving distributed algorithm for fitting Cox models with time-varying coefficients. The limitations of ODACT include that privacy-preserving via aggregate data does rely on relatively large number of data at each individual site, and rigorous quantification of the risk of privacy leaks requires further investigation.

Effect of Histamine-2 Receptor Antagonists on Hypocalcemia after Thyroidectomy: A Retrospective Cohort Study and Sensitivity Analysis.

The objective of this study is to examine the risk of hypocalcemia after thyroidectomy in patients taking histamine-2 receptor antagonists. Retrospective cohort study. Multicenter, single database. Thirty-four thousand two hundred eighteen patients treated with total thyroidectomy from 2011 to 2022 were identified via the TriNetX Research Network. We compared the incidence of transient (0-1 month and 1-6 months following thyroidectomy) and permanent (6-12 months following thyroidectomy) postthyroidectomy hypocalcemia in patients with and without H2 receptor antagonists. Propensity score matching and sensitivity analysis were done to control for additional risk factors. Patients were divided into 2 cohorts: those with an H2 receptor antagonist prescription before surgery (n = 5108) and those without (n = 29,110). 44.9% and 11.6% of thyroidectomy patients taking H2 receptor antagonists had hypocalcemia compared to 38.3% and 8.2% of patients without H2 receptor antagonists at 0 to 1 month and 6 to 12 months, respectively. Patients taking H2 receptor antagonists had a significantly increased risk of experiencing hypocalcemia at 0 to 1 month, 1 to 6 months, and 6 to 12 months. Patients taking H2 receptor antagonists were also at increased risk for visiting the emergency department and receiving intravenous calcium replenishment at 1 and 6 months following surgery. Sensitivity analysis continued to yield significant results at all time points. Patients taking H2 receptor antagonists may be at increased risk of short and long-term hypocalcemia after thyroid surgery. This is the first retrospective cohort study examining the risk of hypocalcemia after thyroidectomy in patients taking H2 receptor antagonists.

SHARED1: Building a network of arts and humanities-based initiatives in mental health and well-being across the globe

This article reports on the learning from a series of workshops organized by the Seeing Arts Health Research EnacteD (SHARED) project that aimed to establish an international network of researchers, arts and health providers and practitioners. Online workshops were designed to provide a platform for exchange of best practices in arts in health research and to encourage a dialogue between various international arts in health researchers and practitioners from six countries across the globe. This exchange was built on participant contributions (three practice-based presentations for each workshop highlighting alignment with community assets, inclusion and partnerships), followed by reflective group discussions. Results show that arts in health initiatives in different contexts globally often share similar strengths and face common challenges. Participants noted the need for networks such as SHARED, where researchers and practitioners can come together to exchange best practice, collaborate on future initiatives and work out solutions for shared challenges.

Likes and Hashtags: Exploring the Potential Relationship Between Social Media use and the Emotional Wellbeing of Oncology Professionals.

To explore the potential relationship between social media (SoMe) and burnout or overall wellbeing within the field of oncology. A cross-sectional study of adult and pediatric oncology professionals conducted using an anonymous electronic survey. The survey was disseminated through the Children's Oncology Group (COG) and the SWOG Cancer Research Network (SWOG) member listservs. The majority of pediatric and adult oncology professionals are not engaging on, with only 873/3000 (29%) using SoMe professionally. Use of SoMe was associated with statistically significant higher incidence of self-reported burnout and poorer self-reported work‒life integration (WLI). However, both groups reported the same degree of career satisfaction and choosing the same career/job again. SoMe users and non-users reported similar overall psychological distress, although the use of SoMe was associated with less severe psychological distress. While SoMe users reported higher rates of burnout and poorer WLI compared to non-users, it was not accompanied by higher levels of psychological distress. Furthermore, there were no differences in career satisfaction. These misalignments require further study.

Meta-analysis of the ability of mutational profiles on the cancer genome atlas to predict prognosis in endometrial carcinoma.

In 2013, The Cancer Genome Atlas Research Network suggested that endometrial carcinoma patients may be reclassified into four molecular prognostic groups. To compare survival of endometrial carcinoma patients with different mutational profiles. Studies reporting survival of endometrial carcinoma patients were identified through systematic searches of four databases. We included relevant studies based on the literature type, data integrity and the methodological quality. The pooled survival data were compared among patients with different mutational profiles. Heterogeneity in the pooled data was assessed using the I2 statistic. Data were meta-analyzed from nine studies involving 4755 patients, who were classified into the following mutational profiles: p53abn, 745 patients (15.6%); MMRd, 1454 patients (30.6%); POLEmut, 351 patients (7.4%); and p53wt, 2205 patients (46.4%). Compared to the p53wt group, the p53abn group showed significantly worse overall survival (OS) (HR 2.31, 95% CI: 1.67-3.19), progression-free survival (PFS) (HR 2.86, 95% CI: 1.45-5.64) and disease-specific survival (HR 2.60, 95% CI: 1.41-4.79); and the MMRd group showed significantly worse OS (HR 1.30, 95% CI: 1.11-1.53) and PFS (HR 1.27, 95% CI: 1.01-1.59). The POLEmut group, in contrast, showed similar survival as the p53wt group. The four mutational profiles for patients with endometrial carcinoma in the Cancer Genome Atlas for Endometrial Cancer are associated with worse to better survival in the trend: p53abn < MMRd < POLEmut ≈ p53wt. Mutational profiling may be useful for stratifying endometrial carcinoma patients by survival risk, which in turn may improve their management.

Prophylactic Use of Cardiac Medications and Survival in Duchenne Muscular Dystrophy.

Prophylactic treatment of left ventricular dysfunction (LVD) in Duchenne muscular dystrophy (DMD) delays onset of LVD, but there is limited data showing impact on survival. Our aim was to describe survival among treated and untreated individuals with DMD. Retrospective, population-based surveillance data from the Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet) were used. We analyzed 327 males with DMD born between 1982 and 2009 who were at least 6 years old at the last visit and who initiated cardiac prophylactic medication before age 14 years. Death status was ascertained through vital record linkages and medical record review. Prophylaxis was defined as cardiac medication use at least 1 year before LVD onset (ejection fraction < 55% or shortening fraction < 28%). Age at first visit, corticosteroid use, scoliosis surgery, initiation of noninvasive ventilation, and loss of ambulation were also coded. Cox Proportional Hazard modeling with time-varying covariates describes associations. Prophylactic cardiac treatment was documented for 27.7% (n = 90); corticosteroids were used by 60.9% (n = 157). Adjusting for age at first visit and MD STARnet site, prophylactic treatment was associated with a 54% lower hazard of death (HR = 0.46, 95% CI = 0.22-0.93) compared to no prophylaxis. Adjusting for selected clinical covariates did not appreciably change the estimate (HR = 0.46, 95% CI = 0.22-0.99). Initiation of cardiac medication when left ventricular function is normal was associated with prolonged survival in this study of males with DMD. Only one-quarter of individuals received this treatment, however, indicating a topic of focus for improving care.

Proton pump inhibitors and all-cause mortality risk among cancer patients

BACKGROUND Proton pump inhibitors (PPIs) are widely used, including among cancer patients, to manage gastroesophageal reflux and other gastric acid-related disorders. Recent evidence suggests associations between long-term PPI use and higher risks for various adverse health outcomes, including greater mortality. AIM To investigate the association between PPI use and all-cause mortality among cancer patients by a comprehensive analysis after adjustment for various confounders and a robust methodological approach to minimize bias. METHODS This retrospective cohort study used data from the TriNetX research network, with electronic health records from multiple healthcare organizations. The study employed a new-user, active comparator design, which compared newly treated PPI users with non-users and newly treated histamine2 receptor antagonists (H2RA) users among adult cancer patients. Newly prescribed PPIs (esomeprazole, lansoprazole, omeprazole, pantoprazole, or rabeprazole) users were compared to non-users or newly prescribed H2RAs (cimetidine, famotidine, nizatidine, or ranitidine) users. The primary outcome was all-cause mortality. Each patient in the main group was matched to a patient in the control group using 1:1 propensity score matching to reduce confounding effects. Multivariable Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence interval (CI). RESULTS During the follow-up period (median 5.4 ± 1.8 years for PPI users and 6.5 ± 1.0 years for non-users), PPI users demonstrated a higher all-cause mortality rate than non-users after 1 year, 2 years, and at the end of follow up (HRs: 2.34-2.72). Compared with H2RA users, PPI users demonstrated a higher rate of all-cause mortality HR: 1.51 (95%CI: 1.41-1.69). Similar results were observed across sensitivity analyses by excluding deaths from the first 9 months and 1-year post-exposure, confirming the robustness of these findings. In a sensitivity analysis, we analyzed all-cause mortality outcomes between former PPI users and individuals who have never used PPIs, providing insights into the long-term effects of past PPI use. In addition, at 1-year follow-up, the analysis revealed a significant difference in mortality rates between former PPI users and non-users (HR: 1.84; 95%CI: 1.82-1.96). CONCLUSION PPI use among cancer patients was associated with a higher risk of all-cause mortality compared to non-users or H2RA users. These findings emphasize the need for cautious use of PPIs in cancer patients and suggest that alternative treatments should be considered when clinically feasible. However, further studies are needed to corroborate our findings, given the significant adverse outcomes in cancer patients.

Effects of early propranolol administration on mortality from severe, traumatic brain injury: a retrospective propensity score-matched registry study.

The role of beta-blockers in severe, traumatic brain injury (TBI) management is debated. Severe TBI may elicit a surge of catecholamines, which has been associated with increased morbidity and mortality. We hypothesize administering propranolol, a non-selective beta-blocker, within 48h of TBI will reduce patient mortality within 30 days of injury. The TriNetX database was leveraged to determine if administering a propranolol within 48h of severe TBI improves outcomes within 30 days of injury. The TriNetX Research Network was used to form two cohorts using retrospective data from 106,294,356 patient profiles from 9/10/2022, which included patients from years 2022 to 2022. The propranolol-receiving cohort included all patients who received the first-instance diagnosis of severe TBI (defined by a Glascow coma scale score of 3-8) and propranolol within 48h of injury. The non-propranolol-receiving cohort included all patients with the same diagnosis of severe TBI but did not receive beta-blockers. The primary outcome of interest was mortality at 30 days. Secondary outcomes included gastrostomy tube placement, neurosurgical intervention in the form of craniotomy, craniectomy, burr hole drainage, seizure, and cardiac arrest. After propensity score-matching, 381 patients were identified for both cohorts. At 30 days post-severe TBI, 22.7% (84) of patients from the cohort that received propranolol, and 30.77% (116) from the cohort that did not, were deceased (OR 0.66), 95% CI [0.48, 0.92]), (p 0.01). TBI patients who received propranolol also had lower odds of requiring neurosurgical intervention, experience seizures, and cardiac arrest. The results of this study demonstrate significantly reduced mortality within 30 days of injury and fewer neurosurgical interventions, seizures, and episodes of cardiac arrest in severe TBI patients who received propranolol within 48h of injury.

Risk of Postoperative Infection in Total Knee Arthroplasty Patients with Preoperative Methicillin-Resistant Staphylococcus aureus (MRSA) Colonization

Background/Objectives: While methicillin-resistant Staphylococcus aureus (MRSA) colonization is a known risk factor for surgical site infections, no definitive recommendations exist regarding preoperative S. aureus screening and decolonization protocols due to inconclusive evidence in Orthopedic Surgery. This study aimed to examine the correlation between preoperative MRSA colonization and postoperative infections in Total Knee Arthroplasty (TKA) patients. Methods: Data from 2005 to 2023 were collected from TriNetX, a global health research network, reviewing 237,360 unique patients. TKA patients were assigned under Current Procedural Terminology, while International Statistical Classification of Diseases Codes were used to identify preoperative comorbidities and postoperative complications. Demographic and analytical statistics were compared between MRSA-positive and control groups before and after propensity matching. Results: The MRSA-positive group had a significantly (p &lt; 0.001) higher proportion of patients over 65 years (47.17% vs. 38.46%), obesity (41.76% vs. 34.67%), smoking disorders (33.36% vs. 19.73%), and diabetes (25.06% vs. 19.85%) compared to the control group. Postoperative complications were significantly (p &lt; 0.001) more frequent in the MRSA-positive group, specifically periprosthetic joint infection (PJI) (4.11% vs. 0.79%, OR = 5.40), deep (0.12% vs. 0.01%, OR = 11.15) and superficial (0.37% vs. 0.09%, OR = 4.17) surgical site infections, and wound dehiscence (1.11% vs. 0.52%, OR = 2.13). The matched analysis confirmed significantly (p &lt; 0.001) higher rates of PJI (4.39% vs. 1.18%, OR = 3.59). Conclusions: Our results illustrated preoperative colonization of MRSA as associated with an increased risk of wound-related complications. Surgeons and patients must consider preoperative MRSA colonization status when deciding if TKA is an optimal treatment option.

Prevalence and characteristics of gastrointestinal disorders, medication use, and diagnostic interventions in pediatric patients with cystic fibrosis: a nested case–control analysis from the TriNetX EMR-derived global research network real-world dataset

BackgroundGastrointestinal (GI) disease in pediatric patients with cystic fibrosis (CF) is a growing concern in the era of improved lung disease; however, the true prevalence of GI diagnoses, medical therapies, and frequency of diagnostic and therapeutic interventions in this population have yet to be explored on a multisystem scale. The aim of the present study was to describe, among pediatric patients with CF (PwCF) compared to a large cohort of healthy controls, the prevalence and types of 1) GI disorders; 2) GI medication use; and 3) GI procedural interventions. MethodsThis was a multicenter case-control analysis using the TriNetX electronic medical record (EMR) global anonymized data platform. Patients were included if they had an ICD9/10 diagnosis code and were between the age of zero to ≤ 21 years between January 1st, 2010, and January 1st, 2020. Those with a history of solid organ transplants were excluded.ResultsThe cohort was comprised of 7,649 patients with a diagnosis of CF (cases) and 22,516,240 patients without CF (controls). The prevalence of any GI disorder was greater in pediatric PwCF compared to those without CF (73% versus &amp;lt;1%). The prevalence of diseases of the biliary tract and pancreas (43% vs. &amp;lt;1%; p&amp;lt;.0001), hepatic disease (8.8% vs. &amp;lt;1%; p&amp;lt;.0001), disease of the esophagus to duodenum (34% vs. &amp;lt;1%; p&amp;lt;.0001), and intestinal disease (43% vs. &amp;lt;1%; p&amp;lt;.0001) were each significantly greater in PwCF (p&amp;lt;0.0001). Furthermore, the frequencies of esophagogastroduodenoscopy (EGD), colonoscopy and endoscopic retrograde cholangiopancreatography (ERCP) were significantly higher among PwCF than controls (9.5% vs. &amp;lt;1%; 2.8%% vs. &amp;lt;1%; and 0.3% vs &amp;lt;.001% respectively; p&amp;lt;0.0001 for all comparisons). ConclusionThe prevalence of GI diagnoses, use of GI medications, and frequency of GI procedures are all higher among pediatric patients PwCF. Prospective multicenter studies are warranted to substantiate these findings, further investigate risk factors for GI disorders, and to describe potential changes in GI disorders with novel CF disease-modifying therapies.

Global Research Trends in Performance-Based Structural Design: A Comprehensive Bibliometric Analysis

In the context of seismic hazard assessment and engineering design, a comprehensive understanding of local geological and geophysical factors is essential. However, previous studies have lacked crucial components such as local soil condition, ground response analysis, topographic influences, active fault characteristics, slip rates, groundwater behaviour, and slope considerations. To ensure the accuracy of the seismic hazard map of a country for the safe and cost-effective design of engineering structures in urban areas, a detailed analysis of these factors is imperative. Moreover, multidisciplinary investigations, such as logic-tree considerations, are needed to enhance seismic hazard maps. As a result, adopting a performance-based approach in structural design has become an essential priority. A performance-based approach allows engineers to design buildings to specified performance levels (IO, LS, CP) even without a reliable seismic hazard map. This approach is akin to a miracle for countries that do not have a reliable seismic hazard map. This study presents a systematic and comprehensive bibliometric analysis of the academic literature pertaining to performance-based design (PBD). By fostering collaborative efforts and expanding research networks, we aim to facilitate the development of coordinated initiatives within the field. Preferred journals, leading countries, leading organisations, and international institutions were identified utilizing the Scopus database. This study examined 3456 PBD-related publications spanning from 1969 to 2023 using VOSviewer version 1.6.19, a bibliometric mapping and visualization software tool. The analysis of co-citations revealed that performance-based design serves as the primary theoretical foundation for structural design and analysis. Furthermore, through a co-word analysis, we tracked the evolution of research topics within the PBD domain over time. This investigation uncovered noteworthy trends, including the steady growth of research output, the increasing prominence of the term “PBD”, and a focus on various types of performance-based analyses.

Identifying Research Priorities for Cognition in CKD: A Delphi Study.

Cognition is a research priority for people living with chronic kidney disease (CKD), but identification of critical research questions is lacking. This study aimed to determine which cognition-related research questions are most important to CKD stakeholders. A modified Delphi technique with 3 survey rounds was used. The study sample included 3 panels (People with lived CKD experience, Researchers, and Clinicians) recruited through international patient and kidney research networks, kidney societies, and snowball sampling with email invitations. Survey rounds were distributed electronically through REDCap. In Round 1 (October 2021-May 2022), respondents contributed three important research questions regarding cognition in CKD (free text). After deduplication and qualitative synthesis, respondents ranked the importance of these questions on a nine-point Likert scale in Round 2 (Feb-April 2023). Questions with mean and median ratings of >7 by at least two respondent panels or rated critically important by the 'lived experience' panel were re-ranked in Round 3 ( Aug-Sept 2023) and assessed for consensus to identify the final list of priority research questions. Respondents (n=152) identified 125 and 44 discrete questions after Rounds 1 and 2, respectively. The final shortlist included 27 questions in 8 categories. The most critical research question identified was "What factors prevent cognitive impairment in people receiving dialysis?" Overall, respondents prioritized questions focusing on prevention and treatment of cognitive impairment. Scores between the panels were significantly different for 16 questions. Those with lived CKD experience prioritized quality of life, researchers emphasized developing interventions to mitigate cognitive impairment, and clinicians prioritized the effect of CKD treatment on cognitive impairment. Through an established consensus methodology involving key stakeholder groups, we identified 27 critical research questions about cognition in CKD. These questions should guide future study design and outcome selection.

Semantic differences between terms associated with the Hungarian and the Ukrainian public education systems

The integration of Ukraine into the European Union is a very complex process which can be facilitated with the development of terminological dictionaries that make the translation of Ukrainian-specific educational, administrative and legal terms much easier. In the spring of 2024, a new terminological research program began within the framework of the Science for the Hungarian Language National Program – Hungarian Terminology Strategy Subprogram. An international research group consisting of members from the Termini Hungarian Language Research Network set out to translate nearly a thousand Hungarian terms from Act CXC of 2011 on National Public Education of Hungary into the state languages of the neighbouring countries, including German, Slovak, Romanian, Serbian, Slovenian, Croatian, and Ukrainian, respectively. The Antal Hodinka Linguistic Research Centre joined the initiative to find the Ukrainian equivalents of Hungarian educational terms, and to develop new terminologies in case of any semantic gaps. The aim of this study is to shed light on the most important semantic differences between the educational and administrative terms connected to the Hungarian and the Ukrainian public education systems. The main problems during the translation process include the development of new terms, the translation of compound expressions, the search for functional equivalents, the grammatical and word-building differences between the Hungarian and the Ukrainian languages, the integration of regional equivalents into the dictionary, the explanation of country-specific educational terms, and the differences between the public education systems of the two countries. The current study is based on the translation of the first 450 terms from the terminological corpus. At the end of the research and the terminological work, a comprehensive online dictionary is going to be developed which will open the door for Hungarian–Ukrainian and Ukrainian–Hungarian translators to create bilingual versions of the countries’ educational laws, and semantic gaps will be filled in relation to the translation of specific terms of the Ukrainian public education system.

IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease – IMMUPARKNET

Parkinson’s disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network – IMMUPARKNET (The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD.

P0842 Paediatric Inflammatory Bowel Diseases: novel agents on the therapeutic horizon

Abstract Background The therapeutic landscape for inflammatory bowel disease (IBD) has advanced considerably over the past two decades with the development of monoclonal antibodies and advanced small molecules. However, only one advanced therapy class is approved for children with IBD. Long delays exist following adult approval, with a median delay of over seven years to paediatric approval (Figure 1).1 With the recent circulation of draft guidance for industry on drug development in paediatric IBD (pIBD) by the US Food and Drug Administration (FDA),2 an opportunity exists to improve clinical trial processes for drug approval in pIBD. The aim of this study is to summarize the landscape of pIBD clinical trials through a review of trial registries. Methods We conducted a cross-sectional review of publicly accessible data from Clinicaltrials.gov and ClinicalTrialsRegister.eu to identify investigational therapeutic agents as well as approved therapeutic agents for the treatment of pIBD. All interventional pIBD studies (&amp;lt;18 years and/or included a paediatric population) listed from the database’s inception to May 13, 2024, were considered for inclusion. Results A total of 3,493 records were identified from Clinicaltrials.gov (2,758) and ClinicalTrialsRegister.eu (735). One-hundred and sixteen completed trials were included in the review. Of those completed trials, 34 studies focused on biologic agents (29%). Novel small molecule agents (spingosine-1-phosphate agonists and Janus kinase inhibitors) were examined in 7 studies (6%). A further 118 IBD trials are actively recruiting paediatric patients. Sixty-five studies are randomised controlled trials and 53 are open-label studies. With regards to biologic agents, 17 trials are exploring the use of approved biologic agents in children and 34 trials are focusing on novel biologic agents. These include etrolizumab, golimumab, guselkumab, mirikizumab, risankizumab, ustekinumab, and vedolizumab. Sixteen trials are recruiting, examining small molecule therapies in pediatrics, to include upadacitinib, tofacitinib, etrasimod, and ozanimod. Conclusion Efforts to hasten the approvals of novel agents in pIBD is paramount to ensure timely access to effective medications. Whilst there is increasing trial activity in the pIBD landscape, approval by regulatory bodies continue to pose barriers. Consideration for novel trial designs and collaboration between research networks could reduce the delay in paediatric marketing approvals. Continued engagement with regulatory bodies and the international pIBD community offers a critical opportunity to advance drug approvals in children with IBD.

Whose “wellbeing” are we talking about? Culture change and the politics of the legal profession’s wellness turn

ABSTRACT Recent years have witnessed growing concern internationally in the topic of wellbeing and mental health across the legal community, an interest reflected in the emergence of a multitude of research studies, policy initiatives, guidelines, networks and reports (e.g. International Bar Association 2021; LawCare 2021). Within recent studies of lawyer wellbeing there has been a growing call to change the culture of law in order to create mentally healthy workplaces. Yet all too often it is unclear what culture change might involve within specific workplace contexts. This paper presents a socio-legal critique of the law's ‘wellbeing turn' and interrogates the underlying conceptualisation and politics of wellbeing in these debates. Following Soon et al. (2023) it suggests there has been insufficient nuanced consideration of the contextual influences that have shaped the wellbeing dynamic law within discrete workplace contexts. It explores how a distinctive kind of ‘wellbeing problem' has emerged across different areas of the law and, grounding the law's turn to wellbeing in a wider social, economic and political context, brings to light questions and concerns about wellbeing, professional identity and commitment relating to ‘life in the law’ in the social justice sector all too often side-stepped in debates about lawyer wellbeing.

Organic Phosphorus in the Terrestrial Environment: an Update on Current Research and Future Directions

Abstract In 2016, a group of experts convened to set priorities for organic phosphorus (P) research, addressing global issues, methodological strengths and weaknesses, and the benefits of understanding the organic P cycle. Seven years later, scientists and students with an interest in organic P reconvened to discuss progress and new insights, and this review highlights recent major research updates. Interest in organic P research has increased since 2016, and new priorities have emerged, including the impact of climate change on organic P, the influence of geopolitical crises on P supplies, and the adoption of sustainable practices like regenerative agriculture. Climate change was a central theme in the 2023 discussions, with an increased emphasis on integrating P and especially organic P into climate change research, which has traditionally focused more on carbon (C) and nitrogen (N). The discussions highlighted disparities in accessing analytical equipment globally, and its consequent impact on research quality and scope. To address these issues, coordinated efforts involving the research community, government policies, and international cooperation are needed, much the same as we see with the climate and biodiversity crises. Promoting sustainable agricultural practices, investing in soil health, and enhancing education and extension services are crucial. Future research should focus on standardizing analytical methods, integrating nutrient balance into models, and exploring soil-microbiome-plant interactions. Regular and intedisciplinary workshops, social media engagement, and the establishment of research networks are recommended to maintain momentum in organic P research. Raising public and stakeholder awareness about the importance of organic P is essential for advancing knowledge in this area.